ALLOGENE THERAPEUTICS INC (ALLO) — insider trading
Health Care · NASDAQ
ALLOGENE THERAPEUTICS INC (ALLO) has 15 reported SEC Form 4 insider transactions in our data, including 4 open-market sales among the most recent 15 (latest 2026-07-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Roberts Zachary | Officer (President and CEO) | Grant / award / vesting (derivative) | 476,190 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Roberts Zachary | Officer (President and CEO) | Grant / award / vesting (derivative) | 134,530 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Barrett Elizabeth A. | Director | Grant / award / vesting (derivative) | 95,400 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Humer Franz B | Director | Grant / award / vesting (derivative) | 95,400 | $0.00 | $0 | Form 4 |
| 2026-06-18 | WITTE OWEN N. | Director | Grant / award / vesting (derivative) | 95,400 | $0.00 | $0 | Form 4 |
| 2026-06-18 | SATO VICKI L | Director | Grant / award / vesting (derivative) | 95,400 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Mayo Stephen | Director | Grant / award / vesting (derivative) | 144,400 | $0.00 | $0 | Form 4 |
| 2026-06-18 | MESSEMER DEBORAH M. | Director | Grant / award / vesting (derivative) | 95,400 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Kazam Joshua A | Director | Grant / award / vesting (derivative) | 95,400 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Kazam Joshua A | Director | Option exercise / conversion (derivative) | 47,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Kazam Joshua A | Director | Option exercise / conversion | 47,700 | $0.00 | $0 | Form 4 |
| 2026-04-21 | Yoshiyama Annie | Officer (SVP, Finance) | Open-market sale | 9,586 | $2.31 | $22.1K | Form 4 |
| 2026-03-31 | Beneski Benjamin Machinas | Officer (SVP, Chief Technical Officer) | Open-market sale | 2,867 | $2.50 | $7.2K | Form 4 |
| 2026-03-16 | Chang David D | Director, Officer (President and CEO) | Open-market sale | 47,763 | $2.47 | $118.0K | Form 4 |
| 2026-03-16 | Beneski Benjamin Machinas | Officer (SVP, Chief Technical Officer) | Open-market sale | 4,835 | $2.47 | $11.9K | Form 4 |
Ask the chat about ALLO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ALLOGENE THERAPEUTICS INC (ALLO).
Last updated 2026-07-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.